A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer

NCT00972309 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

41

Enrollment

NIH

Sponsor class

Conditions

Prostate Specific Antigens
Prostate Neoplasms

Interventions

BIOLOGICAL: T-cell receptor alternate reading frame protein (TARP) peptide vaccine
BIOLOGICAL: T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine

Sponsor

National Cancer Institute (NCI)